相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Re-definition of claudin-low as a breast cancer phenotype
Christian Fougner et al.
NATURE COMMUNICATIONS (2020)
Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors
Florent Peyraud et al.
CANCERS (2020)
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
M. E. Robson et al.
ANNALS OF ONCOLOGY (2019)
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 (vol 28, pg 1700, 2017)
G. Curigliano et al.
ANNALS OF ONCOLOGY (2019)
miR-155 expression in antitumor immunity: The higher the better?
Jean-Jacques Michaille et al.
GENES CHROMOSOMES & CANCER (2019)
Eighth Edition of the AJCC Cancer Staging Manual: Breast Cancer
Armando E. Giuliano et al.
ANNALS OF SURGICAL ONCOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Eric Pujade-Lauraine et al.
LANCET ONCOLOGY (2017)
A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer
Paz Polak et al.
NATURE GENETICS (2017)
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
Helen Davies et al.
NATURE MEDICINE (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes
Nadeem Riaz et al.
NATURE COMMUNICATIONS (2017)
Stepwise analysis of MIR9 loci identifies miR-9-5p to be involved in Oestrogen regulated pathways in breast cancer patients
Raffaela Barbano et al.
SCIENTIFIC REPORTS (2017)
Metabolomics reveals novel blood plasma biomarkers associated to the BRCA1-mutated phenotype of human breast cancer
Barbara Roig et al.
SCIENTIFIC REPORTS (2017)
Improved prediction of PARP inhibitor response and identification of synergizing agents through use of a novel gene expression signature generation algorithm
Daniel J. McGrail et al.
NPJ SYSTEMS BIOLOGY AND APPLICATIONS (2017)
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial
Jonathan A. Ledermann et al.
LANCET ONCOLOGY (2016)
miR-151-5p, targeting chromatin remodeler SMARCA5, as a marker for the BRCAness phenotype
Stefania Tommasi et al.
ONCOTARGET (2016)
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Bella Kaufman et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer
W. Kong et al.
ONCOGENE (2014)
MicroRNA Profiling Implies New Markers of Chemoresistance of Triple-Negative Breast Cancer
Mao Ouyang et al.
PLOS ONE (2014)
Triple-negative and luminal A breast tumors: differential expression of miR-18a-5p, miR-17-5p, and miR-20a-5p
Carlos Marino Cabral Calvano Filho et al.
TUMOR BIOLOGY (2014)
Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes
Kirsten M. Timms et al.
BREAST CANCER RESEARCH (2014)
Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia
Alessandra Ferrajoli et al.
BLOOD (2013)
Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers
E. H. Lips et al.
BRITISH JOURNAL OF CANCER (2013)
Prognostic role of microRNA-155 in various carcinomas: Results from a meta-analysis
Jing He et al.
DISEASE MARKERS (2013)
Clinical Role of microRNAs in Cytogenetically Normal Acute Myeloid Leukemia: miR-155 Upregulation Independently Identifies High-Risk Patients
Guido Marcucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
MiR-155-mediated loss of C/EBPβ shifts the TGF-β response from growth inhibition to epithelial-mesenchymal transition, invasion and metastasis in breast cancer
J. Johansson et al.
ONCOGENE (2013)
miR-125b and miR-155 Contribute to BCL2 Repression and Proliferation in Response to CD40 Ligand (CD154) in Human Leukemic B-cells
Shaun Willimott et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Clinical significance of MicoRNA-155 expression in human breast cancer
Jian Chen et al.
JOURNAL OF SURGICAL ONCOLOGY (2012)
Deregulated miR-155 promotes Fas-mediated apoptosis in human intervertebral disc degeneration by targeting FADD and caspase-3
Hai-Qiang Wang et al.
JOURNAL OF PATHOLOGY (2011)
miR-182-Mediated Downregulation of BRCA1 Impacts DNA Repair and Sensitivity to PARP Inhibitors
Patryk Moskwa et al.
MOLECULAR CELL (2011)
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
Karen A. Gelmon et al.
LANCET ONCOLOGY (2011)
The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings
Thomas Helleday
MOLECULAR ONCOLOGY (2011)
Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155
Suhwan Chang et al.
NATURE MEDICINE (2011)
Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer
Esmerina Tili et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor
Fengjun Wang et al.
GYNECOLOGIC ONCOLOGY (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Andrew Tutt et al.
LANCET (2010)
Modulation of mismatch repair and genomic stability by miR-155
Nicola Valeri et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Linking the Cellular Functions of BRCA Genes to Cancer Pathogenesis and Treatment
Ashok R. Venkitaraman
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE (2009)
MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets
Raffaele Baffa et al.
JOURNAL OF PATHOLOGY (2009)
Robust global micro-RNA profiling with formalin-fixed paraffin-embedded breast cancer tissues
Angela B. Y. Hui et al.
LABORATORY INVESTIGATION (2009)
MicroRNA-155 Is Regulated by the Transforming Growth Factor β/Smad Pathway and Contributes to Epithelial Cell Plasticity by Targeting RhoA
William Kong et al.
MOLECULAR AND CELLULAR BIOLOGY (2008)
MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype
Cherie Blenkiron et al.
GENOME BIOLOGY (2007)
Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer
Anna Bergamaschi et al.
GENES CHROMOSOMES & CANCER (2006)
C/EBPβ at the core of the TGFβ cytostatic response and its evasion in metastatic breast cancer cells
Roger R. Gomis et al.
CANCER CELL (2006)
A microRNA expression signature of human solid tumors defines cancer gene targets
S Volinia et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants
F Elstrodt et al.
CANCER RESEARCH (2006)
C/EBPβ cooperates with RB:E2F to implement RasV12-induced cellular senescence
T Sebastian et al.
EMBO JOURNAL (2005)
REporting recommendations for tumour MARKer prognostic studies (REMARK)
LM McShane et al.
BRITISH JOURNAL OF CANCER (2005)
MicroRNA gene expression deregulation in human breast cancer
MV Iorio et al.
CANCER RESEARCH (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
Repeated observation of breast tumor subtypes in independent gene expression data sets
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Expression of the CCAAT/enhancer-binding proteins C/EBPα, C/EBPβ and C/EBPδ in breast cancer:: correlations with clinicopathologic parameters and cell-cycle regulatory proteins
K Milde-Langosch et al.
BREAST CANCER RESEARCH AND TREATMENT (2003)
Gene expression profiling predicts clinical outcome of breast cancer
LJ van't Veer et al.
NATURE (2002)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)
分享论文
